Why a 'Large and Unjustified' Payment Threshold is Not Consistent with Actavis

Why a 'Large and Unjustified' Payment Threshold is Not Consistent with Actavis
Author :
Publisher :
Total Pages : 10
Release :
ISBN-13 : OCLC:1306244724
ISBN-10 :
Rating : 4/5 ( Downloads)

Book Synopsis Why a 'Large and Unjustified' Payment Threshold is Not Consistent with Actavis by : Michael A. Carrier

Download or read book Why a 'Large and Unjustified' Payment Threshold is Not Consistent with Actavis written by Michael A. Carrier and published by . This book was released on 2016 with total page 10 pages. Available in PDF, EPUB and Kindle. Book excerpt: FTC v. Actavis was a landmark antitrust decision. In rejecting the “scope of the patent” test that had immunized settlements by which brand-name drug firms pay generic companies to delay entering the market (“exclusion payment settlements”), the Supreme Court made clear that such agreements “tend to have significant adverse effects on competition” and could violate the antitrust laws.Some lower courts and defendants have sought to sow ambiguity in the post-Actavis caselaw by creating new thresholds and frameworks not articulated or envisioned by the Court. In particular, they have latched onto the discussion in Actavis of a “large and unjustified” payment. The district court in In re Loestrin 24 FE Antitrust Litigation, for example, imposed a framework that required analysis of (1) whether “there [is] a reverse payment” and (2) whether “that reverse payment is large and unjustified” before addressing (3) the rule of reason. The Loestrin court borrowed this framework from the district court in In re Lamictal Direct Purchaser Antitrust Litigation. And defendants have contended, for example, that “Actavis requires a plaintiff challenging a reverse-payment settlement . . . to prove, as a threshold matter, that the . . . payment was both large and unjustified” and that “under Actavis, [plaintiffs] have to prove that [a] payment was 'large' (as well as unexplained).”This article offers three reasons why a requirement that a plaintiff demonstrate a large and unjustified payment before reaching the Rule of Reason is not consistent with Actavis. First, nearly all of the Court's discussion of large and unjustified payments occurred in contexts having little to do with the antitrust analysis that future courts were to apply. Second, the Court instructed lower courts to apply the Rule of Reason, not a new framework with a threshold it never mentioned. And third, such a threshold is inconsistent with the Court's (1) allowance of shortcuts for plaintiffs to show anticompetitive effects and market power and (2) imposition of the burden on defendants to show justifications for a payment.


Why a 'Large and Unjustified' Payment Threshold is Not Consistent with Actavis Related Books

Why a 'Large and Unjustified' Payment Threshold is Not Consistent with Actavis
Language: en
Pages: 10
Authors: Michael A. Carrier
Categories:
Type: BOOK - Published: 2016 - Publisher:

DOWNLOAD EBOOK

FTC v. Actavis was a landmark antitrust decision. In rejecting the “scope of the patent” test that had immunized settlements by which brand-name drug firms
Actavis and 'Large and Unjustified' Payments
Language: en
Pages: 0
Authors: Michael A. Carrier
Categories:
Type: BOOK - Published: 2013 - Publisher:

DOWNLOAD EBOOK

This short piece responds to Alan Morrison's post on SCOTUSblog that the Supreme Court's Actavis decision is unclear because of its emphasis on “large and unj
IP and Antitrust: An Analysis of Antitrust Principles Applied to Intellectual Property Law, 3rd Edition
Language: en
Pages: 3280
Authors: Hovenkamp, Janis, Lemley, Leslie, Carrier
Categories:
Type: BOOK - Published: 2016-01-01 - Publisher: Wolters Kluwer

DOWNLOAD EBOOK

Regulation, Innovation and Competition in Pharmaceutical Markets
Language: en
Pages: 257
Authors: Margherita Colangelo
Categories: Law
Type: BOOK - Published: 2023-04-20 - Publisher: Bloomsbury Publishing

DOWNLOAD EBOOK

This book explores the fundamental and inextricable relationship between regulation, intellectual property, competition law, and public health in pharmaceutical
The Cambridge Handbook of Antitrust, Intellectual Property, and High Tech
Language: en
Pages: 873
Authors: Roger D. Blair
Categories: Law
Type: BOOK - Published: 2017-04-07 - Publisher: Cambridge University Press

DOWNLOAD EBOOK

This Cambridge Handbook, edited by Roger D. Blair and D. Daniel Sokol, brings together a group of world-renowned professors in the fields of law and economics t